http___www.purchasecipro.org_ga_pfizer-recalls-lung-drug.html_1.xml
1.1 2.1 3.1 4.1 5.1 6.1 6.2 7.1 7.2 8.1 9.1 10.1 10.2 11.1 11.2 12.1 12.2 13.1 13.2 14.1 15.1 15.2 16.1 17.1 18.1 19.1 20.1 21.1 21.2 22.1 22.2
Pfizer recalls lung drug Pfizer Inc is a volunteer with reference to their drug to a threatening lung disease to treat life and studies on the pill the end, after it was linked to potentially fatal liver toxicity. The European Medicines Agency on Friday said the modest-selling drug was withdrawn to the treatment of hypertension pulmonale due to "new information more than two cases of fatal liver damage." Pfizer spokesman Curtis Allen said drug Thelin name is not sold in the United States and in Europe, Canada and Australia, after she had a new liver problem are remembered "that occurs rarely and unpredictably with patients. "The decision on a review of the new security information Strait information based email marketing," he said to all, reports from doctors that they have prescribed. Thelin and similar drugs already carry warnings increased liver enzymes, a fluorescent marker for liver damage as possible. But now the new liver Thelin risk to their overall risks bangs utility preponderate possible, telling everyone. Pfizer, the largest pharmaceutical company in the world, suddenly walked head on Sunday, scrapped U.S. studies Thelin of hypertension pulmonale. Such patients have increased blood pressure in the lung arteries and veins, which dyspnea and other symptoms that can lead to heart failure and early death. More than 1,100 patients have taken Thelin, as they have given life to it in Europe in 2006 and in Australia and Canada the following year. Pfizer in 2008 paid $ 195,000,000 for the company that the product, Encysive Pharmaceuticals develops, despite the U.S. Food and Drug Administration rejected the drug had repeated so because lack of efficacy. Pfizer was in the U.S. study set the end of the test Thelin reward. This is younger in a long line of setbacks for Pfizer, laboratories have not engendered any great selling drugs for more than a decade. "It’s something else in its pipeline, although the wait for (Thelin) was relatively small," said Damien Conover, an analyst at Morningstar. "If this would have admitted to the United States and not the safety side effect, you can have seen so straight burglary at Blockbuster volume of sales to peak hours." Conover said investors are Hemmer called JAK Pfizer, a drug to treat arthritis rheumatoider, and ALK inhibitor for a subset of patients with lung crab adjusted. The two drugs, if she lucky head studies could produce a turnover this year of more than $ 2000000000, he said. Pfizer shares were almost 1.3 percent to $ 16.98 in afternoon trading in New York stick Exchange. The stock has fallen about 18 percent to 52-week high of $ 20.36 in January. Thelin received a sales volume of $ 44,000,000 during the first nine months of 2010, so this is a small product for Pfizer. It competes with Tracleer, a drug of Actelion Ltd which had sales of $ 1400000000 in 2009. Thelin also competes with LETAIRIS of Gilead Sciences Inc which is produced in 2009 a sales volume of $ 184,000,000. Tracleer and Thelin is LETAiRiS all fragments block Endothelin, a protein that triggers a narrowing of blood vessels. Deutsche Bank analyst Richard Parkes said on Friday the new liver to be the problem specific shines Thelin. "Contrary to this the Actelion has a large database of security are produced to show that increases in liver enzyme values with Tracleer can be sure," Parkes said in a research report. The Actelion shares rose nearly 1.3 percent as answering the call of Thelin eliminate competition to Tracleer. Pfizer’s order last year so bought U.S. rivals Wyeth Wyeth in hope, Pfizer drugs would row aging strengthening medicines, including $ 11000000000 Year cholesterol fighter Lipitor, the U.S. antitrust by Heather gene in November 2011 faces. On Sunday, Pfizer CEO Jeffrey Kindler surprised Wall Street with the announcement, he is again the position of rest in "their batteries charged." He gave the company to rein Ian Read, Pfizer Global Drug chief. (Report by Ransdell Pierson and Toni Clarke;. Correction Tim Dobbyn Steve Orlofsky and John Wallace)
1.1 2.1 3.1 4.1 5.1 6.1 6.2 7.1 7.2 8.1 9.1 10.1 10.2 11.1 12.1 12.2 13.1 13.2 14.1 15.1 15.2 16.1 17.1 18.1 19.1 20.1 21.1 22.1 22.2
Pfizer Meabhraíonn drugaí scamhóg Tá Pfizer Inc oibrí deonach le tagairt a drugaí le galar scamhóg bagrach chun cóir leighis a saol agus staidéar ar an piolla an deireadh, tar éis é a nasctha le tocsaineacht ae d'fhéadfadh a bheith marfach. An Ghníomhaireacht Leigheasra Eorpach ar an Aoine, dúirt tarraingíodh siar an druga measartha-díol ar an chóireáil pulmonale Hipirtheannas mar gheall ar "faisnéis nua níos mó ná dhá chás le damáiste ae marfach." Pfizer urlabhraí Curtis Allen dúirt nach bhfuil ainm Thelin drugaí a dhíoltar sna Stáit Aontaithe agus san Eoraip, i gCeanada agus san Astráil, tar éis go raibh sí ina fhadhb ae nua á mheabhrú "annamh a tharlaíonn agus unpredictably le hothair." "Beidh an cinneadh maidir le hathbhreithniú ar na slándála faisnéise margaíochta Caolas nua ríomhphost bunaithe ar eolas," a dúirt sé chun gach tuairisc, ó dhochtúirí go bhfuil siad forordaithe. Thelin agus drugaí den chineál céanna i gcrích cheana féin rabhaidh einsímí ae méadaithe, marcóir fluaraiseacha as damáiste ae agus is féidir. Ach bangs anois ar an riosca Thelin nua ae a rioscaí foriomlán fóntais preponderate is féidir, ag insint do gach duine. Pfizer, an chuideachta cógaisíochta is mó sa domhan, shiúil go tobann ceann ar an Domhnach, scrapped staidéir US Thelin de pulmonale Hipirtheannas. Othar den sórt sin tar éis méadú brú fola i na hartairí scamhóg agus féitheacha, a dyspnea agus comharthaí eile is féidir go dtiocfadh cliseadh croí agus bás go luath. Níos mó ná 1,100 othar ag glacadh Thelin, mar a bhfuil siad tugtha saol dó san Eoraip i 2006 agus san Astráil agus i gCeanada an bhliain dar gcionn. Pfizer i 2008 a íocadh $ 195,000,000 don chuideachta go bhfuil an táirge, forbraíonn Cógaisíocht Encysive, in ainneoin an Bia agus Drugaí Riarachán na Stát Aontaithe dhiúltaigh a bhí arís agus arís eile ar an druga sin mar gheall ar heaspa éifeachtúlachta. Pfizer bhí sa staidéar US leagtha deireadh an luach saothair Thelin tástála. Tá sé seo níos óige i líne fhada setbacks do Pfizer, nach bhfuil saotharlanna engendered aon drugaí mór ag díol ar feadh níos mó ná deich mbliana. "Tá sé rud éigin eile sa phíblíne, cé go raibh an fanacht le haghaidh (Thelin) réasúnta beag," a dúirt Damien Conover, ar anailísí ar Morningstar. "Más rud é go mbeadh sé seo a bheith arna ligean isteach go dtí na Stáit Aontaithe agus nach bhfuil an éifeacht taobh sábháilteachta, is féidir leat feicthe ag buirgléireacht sin díreach ag méid na ndíolachán Blockbuster a bhuaic-am." Conover dúirt infheisteoirí tá Hemmer a dtugtar JAK Pfizer, druga a chóireáil airtríteas rheumatoider, agus ALK inhibitor chun fo-thacar na n-othar le portán scamhóg choigeartú. An dá drugaí, más rud é go bhféadfadh sí staidéir ar cheann t-ádh a tháirgeadh a láimhdeachas na bliana seo de níos mó ná $ 2000000000, a dúirt sé. Bhí beagnach 1.3 faoin gcéad scaireanna Pfizer chun $ 16.98 i trádála tráthnóna i Nua-Eabhrac bata Exchange. Tá an stoc titim faoi 18 faoin gcéad go 52 seachtain-ard de 20.36 $ i mí Eanáir. Thelin Fuair méid díolacháin de $ 44,000,000 i rith an chéad naoi mí den bhliain 2010, agus mar sin is é seo a táirge beag do Pfizer. Iomaíocht sé le Tracleer, druga de Actelion Teo a bhí díolacháin de $ 1400000000 i 2009. Thelin iomaíocht chomh maith le LETAIRIS na nEolaíochtaí Gilead Inc a tháirgtear i 2009 le méid díolacháin de $ 184,000,000. Is Tracleer agus Thelin LETAiRiS gach Endothelin bloc blúirí, le próitéin go triggers caolú ar soithigh fola. Deutsche Bank anailísí Richard Parkes dúirt ar an Aoine an ae nua a bheith ar an fadhb shonrach shines Thelin. "Murab seo tá an Actelion bunachar sonraí mór na slándála a tháirgtear chun a thaispeáint gur féidir le méaduithe i luachanna einsím ae le Tracleer a bheith cinnte," a dúirt Parkes i dtuarascáil taighde. Na scaireanna Actelion ardaigh beagnach 1.3 faoin gcéad mar fhreagairt ar an glao ar iomaíocht a dhíchur Thelin Tracleer. Na bliana seo caite chun Pfizer an cheannaigh sin iomaitheoirí US Wyeth Wyeth i dóchas, bheadh drugaí Pfizer rámhaigh aging leigheasanna a neartú, lena n-áirítear 11000000000 $ Lipitor Trodaire Bliain cholesterol, an frithiontaobhais US ag Heather géine i Samhain 2011 aghaidheanna. Ar Dé Domhnaigh, ionadh Pfizer POF Jeffrey Kindler Wall Street leis an bhfógra, tá sé arís an seasamh de chuid eile i "a gcuid cadhnraí a ghearrtar." Thug sé an chuideachta a rein Ian Léigh, Pfizer príomhfheidhmeannach Drugaí Domhanda. (Tuarascáil Ransdell Pierson agus Toni Clarke;. Ceartú Tim Dobbyn Steve Orlofsky agus John Wallace)